Lyell Immunopharma Inc. has announced new clinical and translational data from its ongoing trial of rondecabtagene autoleucel (ronde-cel, LYL314) in patients with large B-cell lymphoma. The results were presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. As of the September 5, 2025, data cutoff, ronde-cel demonstrated a 93% overall response rate and a 76% complete response rate in the third- or later-line setting, with a median progression-free survival of 18 months. In the second-line setting, patients achieved an 83% overall response rate and a 61% complete response rate. The safety profile was reported as manageable, with no high-grade cytokine release syndrome and 5% or fewer patients experiencing Grade 3 or higher ICANS following dexamethasone prophylaxis. Presentation materials and a webcast replay will be available on the Lyell website.